TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02195011

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-Spheres
Description: Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
Study: NCT04543370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 2 MG/ML
Description: 2 mg/ml syrup

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort 36Mg Tab
Description: 36 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deflazacort 36Mg Tab
Description: 36 mg tablets
Study: NCT01169181

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMES + brain stimulation
Description: Stroke survivors with plegia of affected upper extremity receive either AMES + rTMS or AMES + tDCS.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AMES + brain stimulation
Description: Stroke survivors with plegia of affected upper extremity receive either AMES + rTMS or AMES + tDCS.
Study: NCT03741205

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPEAC System
Description: Surface Electromyography (sEMG) based seizure monitoring and alerting system
Study: NCT02498730

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interval Training
Description: High Intensity Interval Training at 100% VO2Max

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interval Training
Description: High Intensity Interval Training at 100% VO2Max

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Training
Description: Continuous Stimulous at 60% VO2Max
Study: NCT03985865

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraduodenal quinine hydrochloride
Description: A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 10 µmol of quinine hydrochloride per kg body weight was administrated into the duodenum.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intraduodenal denatonium benzoate
Description: A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 1 µmol of denatonium benzoate per kg body weight was administrated into the duodenum.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intraduodenal placebo
Description: A nasogastric feeding tube was positioned into the duodenum, and checked with fluoroscopy. 0.1 ml of water (placebo) per kg body weight was administrated into the duodenum.
Study: NCT01534520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intravaginal insertion of 4mL 2% lidocaine gel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: KY Jelly
Study: NCT04742283

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-126 Ophthalmic Solution 0.002% QD
Description: DE-126 Ophthalmic Solution QD evening and Vehicle QD Morning

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol Maleate Ophthalmic Solution 0.5% BID
Description: Timolol Maleate Ophthalmic Solution BID (morning and evening)
Study: NCT00304603

Intervention type: OTHER
Intervention: No intervention
Description: No treatment was given to the patients as this is an observational study.
Study: NCT02909478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprepitant+Tropisetron
Description: Patients will receive the chemotherapy drugs oxaliplatin,leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus Tropisetron (5mg IV of day1)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone+Tropisetron
Description: Patients will receive the chemotherapy drugs oxaliplatin, leucovorin and 5-fluorouracil as well as the following antiemetic drugs:~Dexamethasone (10 mg IV on day 1 and 5 mg IV days 2, 3) plus Tropisetron (5mg IV of day1)
Study: NCT03223961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPREX
Description: 60 000 U/week for at least 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPREX
Description: 60 000 U/week for at least 12 weeks
Study: NCT03265522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ThinkMed resource at baseline
Description: The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline.
Study: NCT03976869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7594
Description: During treatment period, AZD7594 (360 µg per day) will be administered as oral inhalation via dry powder inhaler or DPI (SD3FL inhaler).
Study: NCT00782587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemophase
Description: 40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled
Study: NCT03265522

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard Care Control
Description: Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 6 month study visit (i.e. delayed intervention).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ThinkMed resource (staged)
Description: This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian
Study: NCT01920035

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: UroCool (Local cooling/hypothermia)
Description: These patients will receive the UroCool device which will be inserted just prior to RARP surgery. The UroCool device will be used to effect localized cooling/hypothermia of the pelvic region prior to and during RARP surgery. It will be removed at the end of surgery.
Study: NCT03889301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-E Video
Description: The E-E video was developed by the research team and chronicles the story of Ana who while enjoying coffee with two family members, shares her challenges with depression and her successful outcome with therapy. The video utilizes the genre of the telenovela which creates an entertaining environment where the audience is captivated by the content and absorbs the messages portrayed.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Discussion
Description: Structured psychoeducation and pamphlet about anxiety and depression.
Study: NCT02969603

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance Imaging
Description: Magnetic Resonance Imaging as reference

Intervention type: OTHER
Group type: OTHER
Intervention: Magnetic Resonance combined with Positron Emission Tomography
Description: Comparison with MRI only, to assess muscular activity, creation of anatomic images of muscle activity and resolution of metabolic activity distribution within exercising skeletal muscle
Study: NCT03396757

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard strategy
Description: RRT is initiated within 12 hours after documentation of serum urea concentration \>40 mmol/l and/or an oliguria/anuria for more than 72 hours. The timing of its initiation will be recorded and RRT will continue until criteria for cessation are observed. This arm corresponds to the delayed strategy in the published AKIKI trial (NEJM 2016),

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Delayed strategy
Description: RRT will be initiated only if one or more of above-mentioned potentially severe situations occur (identical to those used during the observational study) or if serum urea concentration reaches 50 mmol/L (this level being chosen in order to avoid extreme elevations of serum urea levels as mentioned above). The physician in charge will be allowed to try a medical treatment. Patients will not receive RRT whatever the duration of anuria/oliguria if any above-mentioned indication for RRT is not present. When required, RRT will be performed with the same modalities and stopped according to the same criteria as in the no further delayed RRT strategy, with special care to avoid dialysis disequilibrium syndrome (see below).~The decision to initiate RRT in the delayed strategy arm of the trial will have to be approved by the attending physician(s) involved in patient's care in order to make sure that it corresponds to her/his usual practice.
Study: NCT02737033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rhodiola
Description: Rhodiola rosea 800mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: innocuous pill manufactured to mimic Rhodiola
Study: NCT01067443

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome®) and sodium stibogluconate
Description: AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B + miltefosine
Description: AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
Study: NCT00458874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIMT results
Description: Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison normal scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. Interpreting Your CIMT Results tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial.
Study: NCT01906879

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: triple, quadruple, non-bismuth quadruple therapy
Description: triple therapy, quadruple therapy, non-bismuth quadruple therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple, quadruple, non-bismuth quadruple therapy
Description: triple therapy, quadruple therapy, non-bismuth quadruple therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triple, quadruple, non-bismuth quadruple therapy
Description: triple therapy, quadruple therapy, non-bismuth quadruple therapy
Study: NCT04585971

Intervention type: DIAGNOSTIC_TEST
Intervention: Signal intensity gradient
Description: Signal intensity gradient:~In time-of-flight (TOF) MRA, The signal intensities at the iso-point (Φa; signal intensity at position A \[Xa\] along the arterial contour line) and at the inner point (Φb; signal intensity at position B \[Xb\]) were calculated by using a trilinear interpolation algorithm based on the positions and signal intensities in the eight neighboring voxels. The signal intensities of TOF-MRA were normalized to eliminate the offset and scale effects across the MRA datasets of participants. For each iso-point (position A), the SIG was calculated from the difference in signal intensities between points A and B as follows:~Scalar SIG, SI/mm = (Φb - Φa) / │Xb - Xa│ (1)~Vector SIG, SI/mm = (Φb - Φa) n / │Xb - Xa│ (2)
Study: NCT02775240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Digoxin
Description: 0.5 mg (2 x 0.25 mg) Digoxin oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: 0.5 mg (2 x 0.25 mg) Digoxin oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Maribavir
Description: 200mg twice a day for 8 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextromethorphan
Description: 30 mg oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 30 mg oral dose
Study: NCT04061993

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength and Sensory-Motor Training
Description: Early postoperative strength and sensory-motor training after total hip arthroplasty. Training consists of: hip muscles strengthening (focusing on abductors); hip and pelvic stabilization exercises; ankle and knee muscles strengthening (better dissipation of impact forces and femoral inner rotation control); trunk muscles strengthening (stabilization of pelvis and lumbar spine and reduction of local loading).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strength and Sensory-Motor Training
Description: Early postoperative strength and sensory-motor training after total hip arthroplasty. Training consists of: hip muscles strengthening (focusing on abductors); hip and pelvic stabilization exercises; ankle and knee muscles strengthening (better dissipation of impact forces and femoral inner rotation control); trunk muscles strengthening (stabilization of pelvis and lumbar spine and reduction of local loading).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Current Standard Physiotherapy
Description: Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Current Standard Physiotherapy
Description: Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Current Standard Physiotherapy
Description: Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Current Standard Physiotherapy
Description: Mobilisation using a walking aid (usually two crutches, rarely a walker), deep vein thrombosis (DVT) prevention exercises, lower limb range of motion exercises and isometric strengthening program
Study: NCT00600145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Description: 15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00222105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: 50-100 mg day 1-28

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg day 1-4 and 15-18
Study: NCT04358757

Intervention type: PROCEDURE
Intervention: Elective cesarean delivery
Description: scheduled cesarean delivery for maternal / obstetric indications
Study: NCT00526201

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-weeks EnhanceFitness
Description: EnhanceFitness class for 12 weeks, 3 times per week for 1 hour sessions.
Study: NCT02498730

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuous Training
Description: Continuous Stimulous at 60% VO2Max

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Only Dependent Variables Measures
Study: NCT03942874

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Reward Retraining
Description: Adapted behavioral activation group treatment for binge eating with values and cognitive skills integrated

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group Reward Retraining
Description: Adapted behavioral activation group treatment for binge eating with values and cognitive skills integrated
Study: NCT04160611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam 7.5mg
Description: The patient groups differ only in that respect that the intervention group will receive oral midazolam 7.5 g before oocyte aspiration.
Study: NCT03169270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise training
Description: All subjects performed a supervised 8-week, 5 days-week of endurance exercise training program in cycle-ergometer Each session included 5 minutes of warm-up and cool-down pedalling at 30% of peak work-rate (WR) and 50 minutes of interval training. The interval training combined 2 minutes of high-intensity pedalling and 3 minutes of active rest. Work-rate progress during the 8-week period was tailored on individual basis, according to subjects' symptoms, to maximize the training effect. During the first 2 weeks, high intensity pedalling interval was at least 70% of peak WR and active rest interval was at least 40% of peak WR. Thereafter, work-rate was increased by approximately 5% every week up to a maximum of 100% of peak WR during the last 2 weeks for the high intensity period and 50% of peak WR for the active rest. The cycling rate during the sessions was maintained at 60-70 rpm.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise training
Description: All subjects performed a supervised 8-week, 5 days-week of endurance exercise training program in cycle-ergometer Each session included 5 minutes of warm-up and cool-down pedalling at 30% of peak work-rate (WR) and 50 minutes of interval training. The interval training combined 2 minutes of high-intensity pedalling and 3 minutes of active rest. Work-rate progress during the 8-week period was tailored on individual basis, according to subjects' symptoms, to maximize the training effect. During the first 2 weeks, high intensity pedalling interval was at least 70% of peak WR and active rest interval was at least 40% of peak WR. Thereafter, work-rate was increased by approximately 5% every week up to a maximum of 100% of peak WR during the last 2 weeks for the high intensity period and 50% of peak WR for the active rest. The cycling rate during the sessions was maintained at 60-70 rpm.
Study: NCT00526201

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: Participants randomized to the wait-list control group will continue their regular activities for 12 weeks and then be offered the exercise intervention (EnhanceFitness).
Study: NCT05241158

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling with visual aid
Description: patients were counselled about the procedure, complications and the post-procedure recovery phase and shown a 5 minutes animated video of the gastroscopy or colonoscopy procedure

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling
Description: Patients counselled about the procedure, complications and the post-procedure recovery phase
Study: NCT04125537

Intervention type: BEHAVIORAL
Intervention: IHI Breakthrough Collaborative Model
Description: Staff teams at participating dialysis centers take part in a quality improvement/collaborative learning model that was initially planned to include three in-person learning sessions, and three activity sessions during which staff teams at each site use quality improvement processes to implement kidney supportive care best practices from the change package. Technical assistance, education, and quality improvement coaching are provided to the site staff teams throughout the project. Patients at the sites then receive care that has been improved via this staff education and quality improvement activities.
Study: NCT04003714

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Patients in r-TMS group received 5 Hz of r-TMS. R-TMS applied with MagVenture device (MagPro X100, Denmark, 2009) and figure eight coil (MMC 140 parabolic, MagVenture).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Repetitive transcranial Magnetic Stimulation
Description: Control group received sham r-TMS.
Study: NCT01811914

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: intraoperative TTE
Study: NCT00876642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aloe vera gel
Description: The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
Study: NCT00190060

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Transdermal testosterone gel (Testogel 1% )
Description: Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched transdermal placebo gel
Description: Matched transdermal placebo gel, 50mg/d for 6 months
Study: NCT00195650

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
Study: NCT03251326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nabilone
Description: Nabilone capsules (4 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cigarettes (0.0 and 5.6% THC)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol capsules (40mg)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT00971308

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-824393
Description: Capsule, Oral, 50mg, Once Daily, 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-824393
Description: Capsule, Oral, 100mg, Once Daily, 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-824393
Description: Capsule, Oral, 10mg, Once Daily, 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-824393
Description: Capsule. Oral, 1mg, Once Daily, 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-824393
Description: Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
Study: NCT05984251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX168
Description: Administered orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Administered orally.